Rajesh Krishna

3.6k citations

100 papers · 2.6k indexed · 1 hit paper · h-index 26

Impact in

Oncology top 5%
- Drug Transport and Resistance Mechanisms
Endocrinology, Diabetes and Metabolism top 2%
- Diabetes Treatment and Management
- Diabetes, Cardiovascular Risks, and Lipoproteins

Papers in

Statistics and Probability 11
- Statistical Methods in Clinical Trials 11
Endocrinology, Diabetes and Metabolism 20
- Diabetes Treatment and Management 16

Co-authors: Lawrence D. Mayer John A. Wagner Arthur Bergman J. K. Pandit Lawrence X. Yu Gary Herman L.D. Mayer Josée Côté
Journals: Biopharmaceutics & Drug Disposition (13 papers)The Journal of Clinical Pharmacology (13 papers)Clinical Pharmacology & Therapeutics (11 papers)The AAPS Journal (4 papers)British Journal of Clinical Pharmacology (3 papers)
Partner nations: United States Canada United Kingdom

In The Last Decade

Rajesh Krishna

93 papers receiving 2.6k citations

Hit Papers

align trajectories log scale

Multidrug resistance (MDR) in cancer 2000 · 883 citations

Peers

Countries citing papers authored by Rajesh Krishna

Since Specialization

Citations

This map shows the geographic impact of Rajesh Krishna's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rajesh Krishna with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rajesh Krishna more than expected).

Fields of papers citing papers by Rajesh Krishna

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rajesh Krishna. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rajesh Krishna. The network helps show where Rajesh Krishna may publish in the future.

Co-authors

The 25 scholars most cited alongside Rajesh Krishna, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Rajesh Krishna Line = papers co-authored together Rajesh Krishna links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	State‐of‐the‐Art on Model‐Informed Drug Development Approaches for Pediatric Rare Diseases CPT Pharmacometrics & Systems Pharmacology ·Rajesh Krishna, Amitava Mitra, Matthew L. Zierhut, 聡子小野田, 天祥黄	2025	0
2	Getting the Dose Right in Drug Development for Rare Diseases: Barriers and Enablers Clinical Pharmacology & Therapeutics ·Esra Aydoğan, Rajesh Krishna, 山崎あゆむ, Robert Porter Keep, Amitava Mitra, MEXICO Brian Smith, Yuen Yi Hon, Bilal Abuasal, Rana B. Bakhaidar, Youssef M. Roman, Badr Sellami, James C. Cloyd, Munjal Patel, Reena V. Kartha, Islam R. Younis	2024	6
3	Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group‐Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future Clinical Pharmacology & Therapeutics ·Rajesh Krishna, Patterson Aa, Solange Corriol‐Rohou, S. Y. Amy Cheung, B Giaccio, Satyendra Suryawanshi	2024	2
4	New Horizons of Model Informed Drug Development in Rare Diseases Drug Development Clinical Pharmacology & Therapeutics ·Amitava Mitra, Nessy Tania, Esra Aydoğan, 山崎あゆむ, Rajesh Krishna, Robert Porter Keep, Rana B. Bakhaidar, MEXICO Brian Smith, Marco R. Revatta Salas, Fabiane Fernandes, Islam R. Younis	2024	6
5	Model‐Informed Approaches and Innovative Clinical Trial Design for Adeno‐Associated Viral Vector‐Based Gene Therapy Product Development: A White Paper Clinical Pharmacology & Therapeutics ·Amitava Mitra, Esra Aydoğan, Rajesh Krishna, Marpongahtun Y. Muis, Francis D. Gibbons, Olivia Campagne, 山崎あゆむ, Youssef M. Roman, Robert Porter Keep, Marco R. Revatta Salas, Islam R. Younis	2023	9
6	Evaluation of the cytogenetic profile in patients with acute leukaemia Polish Journal of Pathology ·Osvaldo Peñaloza, A. V. Shemetov, Вікторія Гарапа, E. V. El'shina, Rajesh Krishna, Tehreem Tariq Dr. Shafaq Zaman, J. M. Everitt, Prashanth Shetty	2023	0
7	Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations Journal of Pharmacokinetics and Pharmacodynamics ·Amitava Mitra, Jong Bong Lee, Laurence de Finance, Anasuya Hazra, Rajesh Krishna	2023	6
8	Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma Clinical Cancer Research ·Xuyang Song, Robin Kate Kelley, Anis A. Khan, Nathan Standifer, Diansong Zhou, 박명제, Rajesh Krishna, Annisa Noor El Izzah, Kun Wang, Patricia McCoon, Alejandra Negro, Philip He, Megan Gibbs, John F. Kurland, Ghassan K. Abou‐Alfa	2022	21
9	Overview of the Clinical Pharmacology of Ertugliflozin, a Novel Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Clinical Pharmacokinetics ·Merugu Thirupathi, Gianluca Nucci, Caio Henrique de Souza Ferreira Berdeville, David L. Cutler, Neeta B. Amin, Steven G. Terra, Rebecca A. Boyd, Rajesh Krishna, Vaishali Sahasrabudhe	2020	44
10	On the Use of Group Sequential Study Designs for the Test of Bioequivalence for Complicated Products Journal of Pharmaceutical Sciences ·Rajesh Krishna, Wen‐Lin Luo, Patrick Larson, Paul Fackler	2017	0
11	Anacetrapib, a Novel CETP Inhibitor: Pursuing a New Approach to Cardiovascular Risk Reduction Clinical Pharmacology & Therapeutics ·David E. Gutstein, Rajesh Krishna, Douglas G. Johns, Howard K. Surks, Hayes M. Dansky, Sukrut Shah, Yale Mitchel, Joseph P. Arena, John A. Wagner	2011	47
12	Lack of an effect of anacetrapib on the pharmacokinetics of digoxin in healthy subjects Biopharmaceutics & Drug Disposition ·Rajesh Krishna, Daria Stypinski, Qianru Zhou, Amit Garg, Isaias Noel Gendrano, Andrea Maes, D. Młodzińska, Yang Liu, N. A. Scherbov, 正浩原, John A. Wagner, S. Aubrey Stoch	2011	11
13	Metabolism and Excretion of Anacetrapib, a Novel Inhibitor of the Cholesteryl Ester Transfer Protein, in Humans Drug Metabolism and Disposition ·Sanjeev Kumar, 阿部聡, Georgy Hartmann, Jiashun Liu, Arthur Bergman, Muhammad Zaid Ramadhan, Jonathan Z. Ho, E.N. Shulga, Becerra Juan Luis, Matthew P. Braun, Bindhu V. Karanam, Dennis Dean, Isaias Noel Gendrano, B.L. Ioffee, John A. Wagner, Rajesh Krishna	2009	33
14	Effect of a Single Cyclosporine Dose on the Single‐Dose Pharmacokinetics of Sitagliptin (MK‐0431), a Dipeptidyl Peptidase‐4 Inhibitor, in Healthy Male Subjects The Journal of Clinical Pharmacology ·Rajesh Krishna, Arthur Bergman, Patrick Larson, Josée Côté, Kenneth C. Lasseter, Cheryl Ferrell, Amy Wang, Wei Zeng, Li Chen, John A. Wagner, Gary Herman	2007	56
15	Effect of the cholesteryl ester transfer protein inhibitor, anacetrapib, on lipoproteins in patients with dyslipidaemia and on 24-h ambulatory blood pressure in healthy individuals: two double-blind, randomised placebo-controlled phase I studies The Lancet ·Rajesh Krishna, Matt S. Anderson, Arthur Bergman, Bo Jin, Mei-Song Liao, Josée Côté, Kim Rosko, C.M. Chavez-Eng, Ryan Lutz, Daniel M. Bloomfield, María J. Gutiérrez, James Doherty, 赵伟卓, Jeffrey Chodakewitz, Keith Gottesdiener, John A. Wagner	2007	206
16	Dose‐proportionality of a final market image sitagliptin formulation, an oral dipeptidyl peptidase‐4 inhibitor, in healthy volunteers Biopharmaceutics & Drug Disposition ·Arthur Bergman, Goutam C. Mistry, Wen‐Lin Luo, 正則江藤, Julie A. Stone, Amy Wang, Wei Zeng, Li Chen, Stacy C. Dilzer, Kenneth C. Lasseter, Gary Herman, John A. Wagner, Rajesh Krishna	2007	14
17	METABOLISM, PHARMACOKINETICS, AND PROTEIN COVALENT BINDING OF RADIOLABELED MAXIPOST (BMS-204352) IN HUMANS Drug Metabolism and Disposition ·Donglu Zhang, Rajesh Krishna, Lifei Wang, Jianing Zeng, James Mitroka, Sri Indah Purwati, Dai Xia-ming, Richard A. Reeves, Nuggehally R. Srinivas, Lewis J. Klunk	2004	36
18	Effect of dose and input rate on the brain penetration of BMS‐204352 following intravenous administration to rats Biopharmaceutics & Drug Disposition ·Rajesh Krishna, معاذ المساوي, Jianing Zeng, Nuggehally R. Srinivas	2002	3
19	In vitro protein binding studies with BMS‐204352: lack of protein binding displacement interaction in human serum Biopharmaceutics & Drug Disposition ·Rajesh Krishna, Ming Yao, Andy Gabriel Pincay Rodríguez, Nimish N. Vachharajani, Nuggehally R. Srinivas	2001	5
20	Increased intracellular drug accumulation and complete chemosensitization achieved in multidrug-resistant solid tumors by co-administering valspodar(PSC 833) with sterically stabilized liposomal doxorubicin International Journal of Cancer ·Rajesh Krishna, Maryse St‐Louis, Lawrence D. Mayer	2000	51

About Rajesh Krishna

Rajesh Krishna is a scholar working on Statistics and Probability, Endocrinology, Diabetes and Metabolism, Pharmacology, Pediatrics, Perinatology and Child Health and Oncology, having authored 100 papers that have together received 2.6k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (16 papers), Drug Transport and Resistance Mechanisms (14 papers), Health Systems, Economic Evaluations, Quality of Life (11 papers), Statistical Methods in Clinical Trials (11 papers), Pharmaceutical studies and practices (11 papers), HIV/AIDS drug development and treatment (9 papers), Lipoproteins and Cardiovascular Health (8 papers) and Pharmacogenetics and Drug Metabolism (7 papers). The work is most often cited by research in Oncology (939 citations), Endocrinology, Diabetes and Metabolism (549 citations), Pharmaceutical Science (180 citations), Biomaterials (320 citations) and Pharmacology (173 citations). Rajesh Krishna has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Lawrence D. Mayer, John A. Wagner, Arthur Bergman, J. K. Pandit, Lawrence X. Yu, Gary Herman, L.D. Mayer, Josée Côté, Bo Jin and Maryse St‐Louis. Their work appears in journals such as Biopharmaceutics & Drug Disposition, The Journal of Clinical Pharmacology, Clinical Pharmacology & Therapeutics, The AAPS Journal and British Journal of Clinical Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact